carteolol

Trade name: cartrol

Small moleculeapproved

Approved

Dec 28, 1988

Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. The following adverse reactions have been reported: transient eye irritation, burning, tearing, conjunctival hyperemia and edema. Carteolol may cause bradycardia and decreased blood pressure, headache, arrhythmia, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, nausea, depression. Carteolol should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade. — NCATS

Clinical trial activity

5 trials · 3 clinical orgs · 6 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
1

Earliest trial started Oct 1, 2009 (NCT00972426)

Timeline

1980s

  1. Dec 28, 1988

    Earliest FDA Approval

  2. Dec 28, 1988

    AbbVie — NDA Secondary Org

1990s

  1. May 23, 1990

    Novartis — NDA Secondary Org

2000s

  1. Jan 3, 2000

    Sandoz — Marketing Organization

  2. Jan 3, 2000

    Novartis — Marketing Organization

  3. Jan 20, 2000

    Bausch & Lomb — Marketing Organization

  4. Feb 6, 2002

    Apotex — Marketing Organization

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 28, 1988

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2
Mol. weight
292.38 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

Yes

Sources

Also known as

  • abbott-43326
  • abbott-43326
  • cartelol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol
  • carteolol hcl
  • carteolol hcl
  • carteolol hcl
  • carteolol hydrochloride
  • carteolol hydrochloride
  • carteolol hydrochloride
  • carteolol hydrochloride
  • carteololum
  • carteololum
  • cartrol
  • cartrol
  • cartrol
  • dl-carteolol
  • ocupress
  • ocupress
  • opc-1085
  • opc-1085
  • opc-1085
  • teoptic
  • teoptic

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05583474Phase 3Sep 27, 2022Fudan University, Otsuka
NCT02105272Phase 3Apr 1, 2014Otsuka
NCT02105285Phase 3Apr 1, 2014Otsuka
NCT02108288Phase 1Apr 1, 2014Otsuka
NCT00972426Phase 4Oct 1, 2009Government of Taiwan, Otsuka
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
OtsukaFor profit5532009
Fudan UniversityAcademic/Hospital1012022
Government of TaiwanGovernment1012009
3 organizations
Page 1 / 1

Marketing (8)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Dec 28, 1988
AbbottFor profitNDA
ApotexFor profitMKTGFeb 6, 2002
Bausch & LombFor profitMKTGJan 20, 2000
NovartisFor profitNDA2May 23, 1990
NovartisFor profitMKTGJan 3, 2000
SandozFor profitMKTGJan 3, 2000
SandozFor profitSYNJan 3, 2000